Louise Hattingh

  • Citations Per Year
Learn More
BACKGROUND In South Africa, the first HBV vaccine dose is administered at age 6 weeks, leaving a potential window for vertical transmission. Insights into HBV seroprevalence in the vulnerable HIV-infected group are important to drive improvements in surveillance, treatment and prevention. OBJECTIVES We set out to implement a screening program for HBV(More)
Background: The seroprevalence of human parvovirus-4 (PARV4) varies considerably by region. In sub-Saharan Africa, seroprevalence is high in the general population, but little is known about the transmission routes or the prevalence of coinfection with blood-borne viruses, HBV, HCV and HIV.  Methods: To further explore the characteristics of PARV4 in this(More)
54 Background: Sustainable Development Goals and the World Health Organisation (WHO) 55 Global health sector strategy on viral hepatitis have set a challenge for the elimination of 56 hepatitis B virus (HBV) infection as a public health concern by the year 2030. Based on 57 current estimates of 250 million individuals with chronic infection, an intensive(More)
  • 1